Exact Sciences to Acquire Thrive Earlier Detection for ~$2.15B

 Exact Sciences to Acquire Thrive Earlier Detection for ~$2.15B

Exact Sciences to Acquire Thrive Earlier Detection for ~$2.15B

Shots:

  • Exact Sciences to acquire Thrive in all cash & stock transaction for ~2.15B out of which $1.7B would be payable at closing, consisting of 65% in Exact Sciences common stock and 35% in cash along with ~$450M as milestones related to the development and commercialization of a blood-based, multi-cancer screening test. The transaction is expected to be close in Q1’21
  • The acquisition will establish Exact Sciences as a leading competitor in blood-based, multi-cancer screening with the addition of Thrive’s, CancerSEEK. The agreement will accelerate the approval, availability, and adoption of multi-cancer screening
  • Additionally, Exact Sciences also acquires Base Genomics to extend its DNA methylation capabilities. The acquisition will boost Exact Sciences’ efforts in cancer diagnostics across the continuum

Click here ­to­ read full press release/ article | Ref: Exact Sciences | Image: European Coatings

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post